about
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized miceHigh multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacyRedefining the viral reservoirs that prevent HIV-1 eradicationDynamic models of viral replication and latencyBioinformatics and HIV latency.Targeted cytotoxic therapy kills persisting HIV infected cells during ARTReal-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIVPredicting the outcomes of treatment to eradicate the latent reservoir for HIV-1Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Naturally occurring compounds elicit HIV-1 replication in chronically infected promonocytic cells.Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kineticsGenome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infectionPathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.Expression of the memory marker CD45RO on helper T cells in macaquesGenotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency.Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapyA passive-flow microfluidic device for imaging latent HIV activation dynamics in single T cellsDual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.Improved Methods to Detect Low Levels of HIV Using Antibody-Based TechnologiesHIV-1 transcription and latency: an update.Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.Homeostatically Maintained Resting Naive CD4+ T Cells Resist Latent HIV Reactivation.Heat shock protein 90 controls HIV-1 reactivation from latency.Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIVEradication of HIV and Cure of AIDS, Now and How?Towards an HIV-1 cure: measuring the latent reservoir.HIV-1 Eradication: Early Trials (and Tribulations).Emerging Nanomedicine Approaches to Targeting HIV-1 and Antiretroviral Therapy.Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy ApproachEnvelope-specific antibodies and antibody-derived molecules for treating and curing HIV infectionHIV and Stem Cell Transplantation.Position effects influence HIV latency reversal.Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection.Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells.Combining Cell and Gene Therapy in an Effort to Eradicate HIV.
P2860
Q21090483-9F6EB6DE-4993-4CE4-9B8B-17F68363E213Q22242698-86EAFA05-5A47-4346-AC91-045ED80F7489Q26827255-A984EBF9-F17F-485F-88D0-1E3E985BB41BQ26866136-6E865102-723D-4686-B8BC-C0F3F1276FE5Q28081427-DCF2D22E-5B1F-4C2C-84A5-3579BF4AFEBAQ28538598-CE612467-F51A-40ED-B551-ED7019CE1E67Q28551642-765F8A3F-A68D-4E76-838D-D5DC78ECD485Q28655602-263EC96B-16F8-48EB-AF3E-CD759F8F5E10Q33654409-BF7778C9-89B8-4131-ABF7-CAAD0E08E52EQ33678299-705B68E2-4E08-4FC7-8809-ED2C8403377FQ33798207-C37FE7D3-2C64-4053-9CD7-474FB4BD74A5Q34649734-C4FF8E66-53E8-4D65-9E4A-782B1DEAD84FQ34650866-8826620E-447A-4009-AF2D-7F05883FFBF0Q34749384-E5D89353-4CA6-448D-A531-A703CB9B5977Q34984611-3F775BD7-FA3B-4151-9E46-754E09E2647BQ35156765-12A8492E-7BD6-4458-91BA-896B977C3BE6Q35544355-FC268C0B-9CF5-4D7C-ACE7-66DF3F9FC48CQ35637027-576D4B42-114F-4CA0-97C1-E5129E59C71CQ35848096-27DF91D0-0145-48E1-BDF6-828407020635Q36021924-EA5B053B-6B7E-4D4A-9EBD-15AB18F95709Q36266486-5DF9FBA7-D08A-4A8C-A86C-25EB4063E1EDQ36603174-A4584DB7-CBC3-4C3F-A3AB-E6283C73D2DCQ36976156-F24AA924-126B-44B5-8A5A-5F420CCCC334Q37013364-AA27C69A-B24C-4702-A7C6-C5A51720073FQ37336473-C9BE8185-17A3-45D1-906A-B27298F23793Q37429714-27686BDA-BCCE-477A-90B1-87999B2A23A0Q37459228-BAEF41A7-4DAA-42B2-9993-B646B6DCB7B5Q37711958-6D2F3F20-9832-4D8C-B2EA-335D4B31935AQ38070411-9E014915-996C-4564-8C1B-1C9C8A358C6EQ38154888-E55BA38B-60C9-44A2-85FD-C8BE407A3A6DQ38369541-4639A42D-5075-4F4B-9756-C996A3395D28Q38675631-AA491E0F-CC63-4D76-86B7-F17EE05B8529Q38765768-0F0419B1-84FE-4156-B234-4515249221D7Q38777152-B9A207B5-C9BA-4E8D-A538-983038ACAF4CQ38977425-C8EC12CB-A800-4417-888E-04144297E0FDQ39145369-1622D609-550E-4ABA-AA57-4212A475781AQ39167914-33D5186A-7329-4D04-AE2D-E86D7ABF6ACCQ40042102-C822ED12-D934-4386-ADAD-FB3F7B79B3E8Q40361855-3711E065-FDCF-4238-AA86-453A41B8FF09Q40427938-6D8C78ED-3176-4774-86BA-EFDE9046BB78
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Developing strategies for HIV-1 eradication
@en
type
label
Developing strategies for HIV-1 eradication
@en
prefLabel
Developing strategies for HIV-1 eradication
@en
P2860
P356
P1433
P1476
Developing strategies for HIV-1 eradication
@en
P2093
Joel N Blankson
P2860
P304
P356
10.1016/J.IT.2012.07.001
P577
2012-08-03T00:00:00Z